Eli Lilly Guides Higher in 2017 Financial Forecast

The transcript discusses Eli Lilly's financial projections for 2017, highlighting expected growth driven by new products in diabetes and cancer. It addresses the challenges faced with the Alzheimer's drug Solanezumab and outlines future research directions. The conversation also touches on drug pricing issues and the company's efforts to address healthcare system challenges.

Discuss the importance of regulatory actions for new medicines in Eli Lilly's pipeline.

What is the role of partnerships in Eli Lilly's strategy for drug development?

What steps has Eli Lilly taken regarding drug pricing for insulin and diabetes products?